# Trade Mark Journal No.2026/035 28 August 2026

## WO0000001931822 (1,5,42)

Office of origin: United States of America

Date of International Registration:16 March 2026
Date of designation in the UK: 16 March 2026

International priority date claimed: 15 September 2025 (United States of America) (99393442)

Class 1
  Biological preparations for use in industry and science; chemical agents for use in industry and science; biological preparations comprising of small molecules for use in scientific research; bacterial and viral substances other than for medical and veterinary uses; chemicals and biological chemical preparations for use in medical science, namely, for use in biochemical and clinical research.
Class 5
  Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cancer, immune system diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, respiratory diseases and disorders, infectious diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, hematological diseases and disorders, and gastroenterological diseases and disorders.
Class 42
  Scientific research and pharmaceutical development services; development of gene-based medicines; medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation; scientific research in the field of biology, molecular biology, cell biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry, scientific research of vaccines, and antibiotics; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of disease, biomedical, and genomic research; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for the design and characterization of therapeutic products and drug analysis in the field of drug discovery and development; providing online non-downloadable software using artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, molecular, biochemical, and biomarker information, associations, conditions, outcomes, effects and risks.

Weaver Biosciences, Inc.

Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA